Person: YUMUK, PERRAN FULDEN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
YUMUK
First Name
PERRAN FULDEN
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Open Access D-dimer - Can it be a marker for malignant gastric lesions?(TAYLOR & FRANCIS LTD, 2004-12) YUMUK, PERRAN FULDEN; Aliustaoglu, M; Yumuk, PF; Gumus, M; Ekenel, M; Bolukbas, F; Bolukbas, C; Mutlu, N; Basaran, G; Avsar, E; Turhal, NSPublication Open Access Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer(BMC, 2005-12) YUMUK, PERRAN FULDEN; Abacioglu, U; Yumuk, PF; Caglar, H; Sengoz, M; Turhal, NSBackground: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC. Methods: Patients with KPS >= 70, adequate bone marrow reserve, with no prior radiotherapy (RT) and surgery were included. Eighteen patients had received prior induction chemotherapy (CT). G (75 mg/m(2)/week) was infused over 1 hour for 6 weeks. Thoracic RT was given two hours later over 6 weeks at 1.8 Gy/day fractions (total dose of 61.2 Gy). Pulmonary toxicity was evaluated with computed tomography scans in 6 weeks. Results: Median age was 60 years (range, 48-75), median follow-up was 15 months (range, 2-40). Sixty-eight percent of patients were male and median KPS score was 90. Conformal 3D-RT planning was used in 64% of patients. G was given for a median of 5 weeks ( range 1-9). Twelve patients (54.6%) received all planned CT. G was stopped because of intolerance in 6 and death in 2 patients. Seven patients (31.8%) had radiation pneumonitis. Twenty patients were evaluated for overall response, 1 patient (4.5%) had clinical CR, 81.8% had PR while 9.5% had SD. Median overall survival (OS) was 14 +/- 5 months (95% CI 3-25). One- and 2-year OS rates were 55% and 38%. Sixteen patients died of disease-related events (6 with progression of primary tumor, 8 due to metastatic disease), 2 patients died of other causes. One- and 2-year progression- free survival and local control rates were 56%, 27% and 79%, 51%, respectively. Conclusion: G might be used as radiosensitizer for patients with stage III NSCLC who could not receive full doses CT with concurrent RT.Publication Metadata only Epithelioid hemangioendothelioma with multiple organ involvement(WILEY, 2007) ÇELİKEL, ÇİĞDEM; Celikel, Cigdem; Yumuk, P. Fulden; Basaran, Gul; Yildizeli, Berdrettin; Kodalli, Nihat; Ahiskali, RenginEpithelioid hemangioendothelioma is a rare vascular neoplasm of uncertain malignant potential. Various reports document metastatic or concurrent epithelioid hemangioendothelioma in several sites, most commonly with combined lung and liver involvement. The concurrent involvement of multiple sites at presentation may cause diagnostic problems because epithelioid hemangioendothelioma can mimic other neoplastic processes. Although it is a chemoresistant disease, chemotherapy is usually advised for patients with metastatic or concurrent involvement. Here we document the presentation, treatment, and outcome of two cases with concurrent involvement of the lung and liver.Publication Metadata only Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival(KARGER, 2007) ÇELİKEL, ÇİĞDEM; Cabuk, Devrim; Basaran, Gul; Celikel, Cigdem; Dane, Faysal; Yumuk, P. Fulden; Iyikesici, M. Salih; Ekenel, Meltem; Turhal, N. SerdarBackground: Angiogenesis is one of the key steps in solid tumor growth and metastasis. We planned to investigate the prognostic significance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1 alpha (HIF-1 alpha) and CD34 expressions as markers of angiogenesis in gastric cancer. Patients and Methods: We retrospectively reviewed the medical records of 51 gastric cancer patients who had total or subtotal gastrectomy at Marmara University Hospital from 1990 to 2004 and evaluated the expression of VEGF, HIF-1 alpha and CD34 by immunohistochemistry in their archival tumor tissues. We recorded the clinical and pathological characteristics of these patients and analyzed their survival outcome. Results: Thirty out of 51 patients were males. The median age was 63 years (range 34-81). The median follow-up was 17 months. Thirty-six patients had node-positive disease. The majority of patients (n = 43) had T2 and T3 disease. Vascular and lymphatic invasions were present in 57 and 77% of tumors, respectively. VEGF and HIF-1 alpha were positive in 65 and 71% of tumors. The median CD34 staining score was 19 (3-68). VEGF, HIF-1 alpha and CD34 expressions were more frequent in tumors without serosal invasion (p = 0.01, p = 0.01 and p = 0.003, respectively). CD34 expression was significantly more frequent in tumors with VEGF and HIF-1 alpha expression (p = 0.00, p = 0.00). HIF-1 alpha expression was more frequent in tumors with VEGF expression (p = 0.00). The 5year overall survival was 45%. VEGF, HIF-1 alpha, CD34 expressions and other pathological characteristics were found to have no impact on survival. Conclusion: VEGF, HIF-1 alpha and CD34 expressions were more common in tumors without serosal invasion. As a future perspective, biological agents targeting VEGF and HIF-1 alpha might be more effective at earlier stages of gastric cancer. Copyright (c) 2007 S. Karger AG, Basel.Publication Metadata only Outcome in carcinoma of the uterus with papillary serous and clear cell histology: A Turkish Oncology Group Study(AMER SOC CLINICAL ONCOLOGY, 2008) ATASOY, BESTE MELEK; Yumuk, P. F.; Kucucuk, S.; Atasoy, B. M.; Aydin, A.; Cicin, I.; Yildiz, F.; Atkovar, G.; Aslay, I.; Okkan, S.; Topuz, E.Publication Metadata only Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer(WILEY, 2009) DANE, FAYSAL; Kefeli, U.; Dane, F.; Yumuk, P. F.; Karamanoglu, A.; Iyikesici, S.; Basaran, G.; Turhal, N. S.The long-term use of subcutaneous implanted ports for chemotherapy in cancer patients has been associated with the occurrence of thrombosis and infection. In this study, we compared the safety and efficacy of administration of 1000 U of heparin flushes in prolonged interval (every 6 weeks) with standard dose and schedule (500 U every 4 weeks) for port-related infections and thrombosis during periods of non-use. Data were collected retrospectively from patients treated for various cancer types (matched as 2: 1 for age, gender, stage of the disease). Patients who had diseases that could cause thrombosis or bleeding in their past medical history, or were taking oral anticoagulants, or had contraindications for heparin usage were excluded. After completing their chemotherapy, 59 patients received prolonged interval, while 30 patients received standard schedule. All patients were followed for at least 1 year. No clinically documented port-related infection or thrombosis has been found in both groups. Also, none of the devices was removed during this time. Prophylactic flushing of central venous ports with 1000 U of heparin in every 6 weeks might be a safe, easy, cheaper, comfortable and effective alternative to standard dose and schedule for preventing thrombosis and infections.Publication Metadata only Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde radyoterapi̇yle eş zamanli tegafur urasi̇l uft foli̇ni̇k asi̇t fa uygulamasi tolerabi̇li̇te değerlendi̇rmesi̇(2006-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ATASOY B. M. , ABACIOĞLU U., ÖZGEN Z., DANE F., YUMUK P. F. , MAYADAĞLI A., TURHAL S., ŞENGÖZ K. M.Publication Metadata only Benefit from adjuvant anthracyclines according to hormone receptor status(AMER SOC CLINICAL ONCOLOGY, 2008) DANE, FAYSAL; Basaran, G. Atalay; Cabuk, D.; Teomete, M.; Gulluoglu, B.; Kaya, H.; Dane, F.; Yumuk, P. F.; Turhal, N. S.Publication Metadata only Limited painful mouth opening(W B SAUNDERS CO, 2005) YUMUK, PERRAN FULDEN; Guler, N; Yumuk, PF; Ilguy, D; Gac, V; Greer, JPublication Metadata only Does the incidence of anal canal cancers differ in Moslem societies?(SPRINGER, 2005) DANE, FAYSAL; Yumuk, PF; Abacioglu, U; Demir, G; Cabuk, D; Dane, F; Gumus, M; Ozguroglu, M; Ekenel, M; Basaran, G; Turhal, NS